A study by researchers at Georgia State University's Institute of Biomedical Sciences has found a new universal flu vaccine has been found to protect against influenza B viruses that offer broad defenses against different strains and improve immune protection.
The U.S. Food and Drug Administration has approved Samsung Bioepis; Halima (adalimumab-bwwd) for the treatment of several autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's disease.
U.S. researchers have developed a new mRNA vaccine against cancer that delivers the drug directly to the lymphatic system and simulates a strong immune response.
U.S. scientists have developed a new genomic test that can predict a patient's risk of developing severe COVID-19, an advance that could help doctors quickly begin tailored treatment.
Results of a recent study shows Pfizer's experimental vaccine for respiratory syncytial virus is nearly 86 percent effective in preventing severe illness in older adults.
An experimental vaccine shows promise for protecting mice from the respiratory syncytial virus, the pathogen that most commonly causes the chest infection bronchiolitis in young children.
Two million dollars in funding has been awarded to the American Academy of Pediatrics to establish a National Center of Excellence on Social Media and Mental Wellness.
The World Health Organization has published its first guideline for Ebola virus disease therapeutics, with new strong recommendations for the use of two monoclonal antibodies.
The U.S. Department of Health and Human Services will provide approximately $11 million to support the first U.S.-based fill and finish manufacturing of JYNNEOS, a vaccine approved to prevent smallpox and monkeypox.
In a Phase II trial of participants with hepatic disease associated with congenital alpha1-antitrypsin deficiency, subcutaneous administration of fazirsitran, an investigational RNA interference therapeutic, reduced both serum and hepatic levels of the mutant hepatotoxic AAT protein Z-AAT, with concurrent improvements in enzymatic and histological markers of liver function.
Subcutaneous administration of marstacimab, an investigational human monoclonal antibody targeting tissue factor pathway inhibitor, resulted in a roughly 10-fold lower annualized bleeding rate in 26 hemophilia patients than comparable control individuals in previous clinical trials who were treated on-demand with recombinant factor replacement therapy.
Dutch investigators conducted a systematic review and meta-analysis of studies on the effectiveness of IVIG treatment of this specific population.
